Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short term Debt (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Short term Debt for 3 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt rose 373.46% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 373.46% increase, with the full-year FY2025 number at $7.3 million, up 373.46% from a year prior.
  • Short term Debt was $7.3 million for Q4 2025 at Rhythm Pharmaceuticals, up from $5.6 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $7.3 million in Q4 2025 to a low of $1.5 million in Q4 2024.